Clinical Trials Logo

Adult ADHD clinical trials

View clinical trials related to Adult ADHD.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01939353 Completed - Adult ADHD Clinical Trials

Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder

Start date: October 3, 2013
Phase: Phase 2
Study type: Interventional

This was a Phase 2 exploratory study to evaluate the efficacy and safety of EB-1020 SR (centanafadine sustained release [CTN SR]) in treating participants who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for Attention-Deficit Hyperactivity Disorder (ADHD) on the Mini International Neuropsychiatric Interview Plus, Version 6.0 (M.I.N.I.-Plus). Evaluations included determining an effectiveness signal for ADHD and related symptoms and exploring dosing, tolerability, onset of action, and duration of effect. Dose-response/tolerability relationships with CTN SR were also explored. The 1-week placebo run-in [single-blind (SB)] was also used for informal safety comparison purposes.

NCT ID: NCT01012375 Completed - Adult ADHD Clinical Trials

Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.

Start date: November 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether 2 weeks of treatment with AZD1446 compared to placebo improves ADHD symptoms and is well tolerated.

NCT ID: NCT00318981 Completed - Adult ADHD Clinical Trials

Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD

Start date: December 2004
Phase: Phase 4
Study type: Interventional

This study involves a 7 week dose-response trial of Concerta™ methylphenidate for mothers of children with ADHD who have ADHD themselves. The aim of this study is to assess the efficacy of Concerta™ in improving adult ADHD symptoms and impairments (primary outcome), as well as observed and reported parenting (secondary outcome). The researchers hypothesize that Concerta™ will significantly decrease mothers ADHD symptoms and impairment, as well as improve observed and reported parenting